CANbridge Pharmaceuticals lands $43m Series E

China and Boston-based CANbridge Pharmaceuticals Inc, a developer of drugs to treat rare diseases and targeted cancers, has raised $43 million in Series E financing.

China and Boston-based CANbridge Pharmaceuticals Inc, a developer of drugs to treat rare diseases and targeted cancers, has raised $43 million in Series E financing. The lead backer was 3W Fund Management. Other investors in the round included Casdin Capital, Summer Capital, SPDBI and Yaly Capital.

Source: Press Release